Rep. Gilbert Ray Cisneros, Jr. Buys Vaxcyte, Inc. (NASDAQ:PCVX) Shares

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Vaxcyte, Inc. (NASDAQ:PCVX). In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Vaxcyte stock on April 28th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Beiersdorf Aktiengesellschaft OTCMKTS: BDRFF on 5/2/2025.
• Purchased $1,001 - $15,000 in shares of Alkami Technology NASDAQ: ALKT on 4/30/2025.
• Purchased $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DXC Technology NYSE: DXC on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DOW NYSE: DOW on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Zions Bancorporation, National Association NASDAQ: ZION on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of O'Reilly Automotive NASDAQ: ORLY on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of McKesson NYSE: MCK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Humana NYSE: HUM on 4/29/2025.

Vaxcyte Price Performance

PCVX opened at $29.00 on Thursday. The company's 50 day moving average price is $48.25 and its two-hundred day moving average price is $75.86. The firm has a market capitalization of $3.74 billion, a price-to-earnings ratio of -6.30 and a beta of 1.27. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same quarter last year, the business posted ($0.85) earnings per share. As a group, equities research analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Hedge Funds Weigh In On Vaxcyte

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its stake in Vaxcyte by 53.7% during the 4th quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock worth $5,916,000 after buying an additional 25,257 shares during the period. Diversified Trust Co bought a new stake in shares of Vaxcyte during the fourth quarter valued at approximately $1,433,000. China Universal Asset Management Co. Ltd. raised its position in shares of Vaxcyte by 23.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock worth $2,163,000 after purchasing an additional 4,962 shares during the period. TimesSquare Capital Management LLC lifted its holdings in shares of Vaxcyte by 53.7% in the 4th quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock worth $33,860,000 after purchasing an additional 144,516 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in Vaxcyte by 70.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock valued at $49,418,000 after purchasing an additional 246,049 shares during the period. Institutional investors own 96.78% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. The Goldman Sachs Group lowered their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Bank of America decreased their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Guggenheim restated a "buy" rating and issued a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 price target on shares of Vaxcyte in a research report on Tuesday, April 8th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $136.50.

Insider Buying and Selling at Vaxcyte

In other news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total transaction of $670,800.00. Following the completion of the transaction, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,180,820.35. This trade represents a 6.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.10% of the stock is currently owned by company insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.